Skip to main content

Repare Therapeutics Inc.

RPTXDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001808158

Repare Therapeutics Inc. was delisted in 2026; its insiders filed their last Form 4 on Jan 30, 2026; 46 institutions reported holding it in 13F filings for Q4 2025, worth $65.7M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Repare Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Repare Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Repare Therapeutics Inc.
NameTitleLast reported holdingLast filingFilings, past year
Biotechnology Value Fund L P10% Owner0Jan 30, 20261
BVF Partners L P10% Owner0Jan 30, 20261
BVF Inc10% Owner0Jan 30, 20261
Biotechnology Value Fund II LPOther: See Explanation of Responses0Jan 30, 20261
Lampert Mark N10% Owner0Jan 30, 20261
Biotechnology Value Trading Fund OS LPOther: See Explanation of Responses0Jan 30, 20261
BVF Partners OS Ltd.Other: See Explanation of Responses0Jan 30, 20261
BVF I GP LLC10% Owner0Jan 30, 20261
BVF II GP LLCOther: See Explanation of Responses0Jan 30, 20261
BVF GP Holdings LLC10% Owner0Jan 30, 20261
Rhoads Ann DDirector0Jan 28, 20261
Schafer CarolDirector0Jan 28, 20261
Civik ThomasDirector0Jan 28, 20261
Forte SteveEVP, CHIEF FINANCIAL OFFICER0Jan 28, 20261
Alves Sandra Isabelle BarrosSVP, Finance and CAO0Jan 28, 20261
Segal Lloyd MitchellPRESIDENT AND CEO124,394Mar 14, 20250
Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICER80,297Mar 14, 20250
Koehler MariaEVP, CHIEF MEDICAL OFFICER227,813Mar 14, 20250
Molineaux SusanDirector–Jun 20, 20240
Bonita David PDirector96,190IndirectJun 20, 20240
Morrison BriggsDirector–Jun 20, 20240
Stein Steven HDirector–Jun 20, 20240
Kulkarni SamarthDirector–Jun 20, 20240
Foley ToddDirector2,242,636IndirectJun 12, 20230
Jerel DavisDirector25,131Jan 3, 20230
Versant Vantage I, L.P.10% Owner0IndirectJun 7, 20220
Versant Vantage I GP, L.P.10% Owner0IndirectJun 7, 20220
Versant Vantage I GP-GP, LLC10% Owner0IndirectJun 7, 20220
Versant Affiliates Fund V, L.P.10% Owner0IndirectJun 7, 20220
Versant Venture Capital V, L.P.10% Owner0IndirectJun 7, 20220
Versant Ophthalmic Affiliates I, L.P.10% Owner0IndirectJun 7, 20220
Versant Venture Capital V (Canada), LP10% Owner0IndirectJun 7, 20220
Versant Ventures V GP-GP (Canada), Inc.10% Owner0IndirectJun 7, 20220
Versant Ventures V, LLC10% Owner0IndirectJun 7, 20220
Versant Venture Capital VI, L.P.10% Owner0IndirectJun 7, 20220
Versant Ventures V (Canada), L.P.10% Owner0IndirectJun 7, 20220
Versant Ventures VI GP-GP, LLC10% Owner0IndirectJun 7, 20220
Versant Ventures VI GP, L.P.10% Owner0IndirectJun 7, 20220
OrbiMed Advisors LLCDirector96,190IndirectSep 8, 20210
OrbiMed Capital LLCDirector96,190IndirectSep 8, 20210
OrbiMed Capital GP VII LLCDirector96,190IndirectSep 8, 20210
Gadicke Ansbert10% Owner3,882,485IndirectJul 13, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 14, 2025 (view filing)Mar 122 daysKoehler MariaEVP, CHIEF MEDICAL OFFICERSSale−3.60K$1.14−$4.10K−1.6%227.8K after
Mar 14, 2025 (view filing)Mar 122 daysZinda MichaelEVP, CHIEF SCIENTIFIC OFFICERSSale−5.61K$1.14−$6.40K−6.5%80.3K after
Mar 14, 2025 (view filing)Mar 122 daysForte SteveEVP, CHIEF FINANCIAL OFFICERSSale−6.88K$1.14−$7.85K−11.2%54.8K after
Mar 14, 2025 (view filing)Mar 122 daysSegal Lloyd MitchellPRESIDENT AND CEOSSale−21.2K$1.14−$24.1K−14.5%124.4K after
Apr 1, 2024 (view filing)Mar 28-Apr 14 daysSegal Lloyd MitchellPRESIDENT AND CEOSSale−5.14K$4.62−$23.8K−4.6%107.6K after2 lots10b5-1
Apr 1, 2024 (view filing)Mar 28-Apr 14 daysForte SteveEVP, CHIEF FINANCIAL OFFICERSSale−1.61K$4.62−$7.45K−3.5%44.8K after2 lots10b5-1
Apr 1, 2024 (view filing)Mar 28-Apr 14 daysZinda MichaelEVP, CHIEF SCIENTIFIC OFFICERSSale−860$4.65−$4.00K−1.2%71.9K after2 lots10b5-1
Apr 1, 2024 (view filing)Mar 28-Apr 14 daysKoehler MariaEVP, CHIEF MEDICAL OFFICERSSale−800$4.65−$3.72K−0.3%231.4K after2 lots10b5-1
Mar 27, 2024 (view filing)Mar 25-272 daysForte SteveEVP, CHIEF FINANCIAL OFFICERSSale−2.48K$4.67−$11.6K−5.5%42.2K after3 lots10b5-1
Mar 27, 2024 (view filing)Mar 25-272 daysZinda MichaelEVP, CHIEF SCIENTIFIC OFFICERSSale−1.35K$4.67−$6.30K−1.8%72.8K after3 lots10b5-1
Mar 27, 2024 (view filing)Mar 25-272 daysKoehler MariaEVP, CHIEF MEDICAL OFFICERSSale−1.50K$4.67−$7.00K−0.6%232.2K after3 lots10b5-1
Mar 27, 2024 (view filing)Mar 25-272 daysSegal Lloyd MitchellPRESIDENT AND CEOSSale−7.95K$4.69−$37.3K−8.7%83.9K after3 lots10b5-1
Nov 17, 2023 (view filing)4:54 PM ETNov 15-162 daysBiotechnology Value Fund L P and 9 others10% OwnerPPurchaseCommon Shares, no par value+1.23M$5.09+$6.25MNew position548.9K after6 lots
Nov 3, 2023 (view filing)5:37 PM ETNov 21 dayBiotechnology Value Fund L P and 9 others10% OwnerPPurchaseCommon Shares, no par value+783.7K$3.60+$2.82MNew position485.1K after3 lots
Jun 9, 2023 (view filing)Jun 72 daysZinda MichaelEVP, Chief Scientific OfficerSSale−6.40K$12.03−$77.0K−9.2%63.0K after10b5-1
Jun 9, 2023 (view filing)Jun 81 dayZinda MichaelEVP, Chief Scientific OfficerSSale+2.87K$12.02+$34.5K+5.0%60.1K after10b5-1
Jun 7, 2023 (view filing)Jun 61 dayZinda MichaelEVP, Chief Scientific OfficerSSale−1.20K$12.04−$14.4K−1.7%69.4K after10b5-1
Dec 13, 2022 (view filing)Dec 94 daysJerel DavisDirectorSSale−250.0K$16.00−$4.00M−10.7%2.09M after
Jun 15, 2022 (view filing)6:15 PM ETJun 132 daysBiotechnology Value Fund L P and 9 others10% OwnerPPurchaseCommon Shares, no par value+149.2K$12.73+$1.90M+56.6%412.6K after3 lots
Jun 7, 2022 (view filing)4:37 PM ETJun 34 daysVersant Vantage I, L.P. and 2 others10% OwnerSSale−750.0K$12.25−$9.19M−87.1%111.5K after5 lotsDuplicate filing
Jun 7, 2022 (view filing)4:36 PM ETJun 34 daysVersant Affiliates Fund V, L.P. and 9 others10% OwnerSSale−750.0K$12.25−$9.19M−87.1%111.5K after5 lots
Jun 7, 2022 (view filing)Jun 34 daysJerel DavisDirector, 10% OwnerSSale−750.0K$12.25−$9.19M−87.1%111.5K after5 lots
Jun 6, 2022 (view filing)6:14 PM ETJun 2-64 daysBiotechnology Value Fund L P and 9 others10% OwnerPPurchaseCommon Shares, no par value+1.84M$11.90+$21.9MNew position406.4K after9 lots
May 20, 2022 (view filing)6:09 PM ETMay 182 daysBiotechnology Value Fund L P and 9 othersOther: See Explanation of ResponsesPPurchaseCommon Shares, no par value+420.0K$8.50+$3.57MNew position313.4K after3 lots
Mar 16, 2022 (view filing)Mar 151 dayZinda MichaelEVP, Chief Science OfficerSSale−533$11.30−$6.02K−1.1%46.0K after
Jan 21, 2022 (view filing)5:12 PM ETJan 192 daysBiotechnology Value Fund L P and 9 othersOther: See Explanation of ResponsesPPurchaseCommon Shares, no par value+998.0K$14.10+$14.1MNew position307.6K after3 lots
Nov 18, 2021 (view filing)Nov 162 daysCivik ThomasDirectorPPurchase+7.50K$28.08+$210.6KNew position7.50K after
Nov 17, 2021 (view filing)Nov 152 daysZinda MichaelEVP, Chief Science OfficerSSale−20.0K$27.33−$546.6K−97.4%533 after2 lots
Sep 8, 2021 (view filing)6:18 PM ETSep 3-75 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−8.08K$33.99−$274.8K−7.8%96.2K after4 lotsDuplicate filing
Sep 8, 2021 (view filing)Sep 3-75 daysBonita David PDirectorSSale−8.08K$33.99−$274.8K−7.8%96.2K after4 lots
Sep 2, 2021 (view filing)8:27 PM ETAug 31-Sep 22 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−37.9K$34.08−$1.29M−28.2%96.4K after6 lotsDuplicate filing
Sep 2, 2021 (view filing)Aug 31-Sep 22 daysBonita David PDirectorSSale−37.9K$34.08−$1.29M−28.2%96.4K after6 lots
Aug 30, 2021 (view filing)6:37 PM ETAug 26-304 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−18.1K$34.07−$615.7K−15.6%97.5K after6 lotsDuplicate filing
Aug 30, 2021 (view filing)Aug 26-304 daysBonita David PDirectorSSale−18.1K$34.07−$615.7K−15.6%97.5K after6 lots
Aug 25, 2021 (view filing)8:43 PM ETAug 23-252 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−18.2K$34.17−$622.4K−15.7%98.1K after6 lotsDuplicate filing
Aug 25, 2021 (view filing)Aug 23-252 daysBonita David PDirectorSSale−18.2K$34.17−$622.4K−15.7%98.1K after6 lots
Aug 25, 2021 (view filing)Aug 17-188 daysLateBonita David PDirectorSSale−20.3K$34.10−$693.2K−17.1%98.6K after4 lotsDuplicate filing
Aug 20, 2021 (view filing)Aug 164 daysLateZinda MichaelEVP, Chief Science OfficerSSale−15.0K$33.99−$509.9K−42.2%20.5K after2 lots
Aug 19, 2021 (view filing)8:55 PM ETAug 17-182 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−20.3K$34.10−$693.2K−17.1%98.6K after4 lotsDuplicate filing
Aug 19, 2021 (view filing)Aug 17-182 daysBonita David PDirectorSSale−20.3K$34.10−$693.2K−17.1%98.6K after4 lots
Jul 13, 2021 (view filing)Jul 9-124 daysFoley ToddDirectorSSale−27.4K$33.55−$917.7K−1.2%2.24M after3 lots
Jul 13, 2021 (view filing)Jul 9-124 daysGadicke Ansbert10% OwnerSSale−62.1K$33.55−$2.08M−1.6%3.88M after3 lots